Additionally, CLDN6 has a high accuracy in predicting acute myeloid leukemia (LAML), testicular germ cell tumors (TGCT), ovarian serous cystadenocarcinoma (OV), and uterine carcinosarcoma (UCS) while having notable correlations with the overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) of uterine corpus endometrial carcinoma (UCEC), adrenocortical carcinoma (ACC), bladder urothelial carcinoma (BLCA), and stomach adenocarcinoma (STAD). The gene discussed is CLDN6; the disease is bladder transitional cell carcinoma.